Market Access Why reshoring drug production means embracing continuous man... Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions.
Views & Analysis Digital tools driving innovative clinical trials The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the cl
Patients From trial design for patients to trial design with patients... At the 2022 Drug Information Association (DIA) annual meeting last week, it was
Events Partner Content Next Generation Lipid-Based Nanoparticles Delivery Summit | ... Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue
R&D Understanding the microbiome as an ‘overlooked critical orga... Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area.
Events Partner Content Welcome to 1st Rare & Genetic Neurodegenerative Drug Dev... Developing R&G neurodegenerative therapies
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
